

Figures and outlook as expected

DT's Q4 results were largely in line with estimates as revenue declined by 6% y/y while EBITA was down EUR 1.5m to EUR 3.7m. Security applications declined even more than we estimated while medical was clearly stronger, leading DT's figures very close to our estimates. DT expects to see double-digit growth over H1'26, as previously indicated.

- DT Q4 revenue decreased by 6.1% y/y to EUR 29.7m vs the EUR 29.4m/29.2m Evli/consensus estimates, while adjusted EBITA was EUR 3.7m vs the EUR 3.7m/4.1m Evli/consensus estimates. Profitability was hit by lower sales as well as product mix tilted towards MBU. The end of the lifecycle of an analog product family led to higher costs, weighing on profitability. DT revenue remained flat on fixed FX basis.
- Medical (MBU) revenue increased by 19.1% y/y to EUR 14.9m, compared to our EUR 12.6m estimate. The Chinese market drove growth.
- Security (SBU) decreased by 28.5% y/y to EUR 10.0m vs our EUR 11.7m estimate. A strong comparison period, the after-effects of the aviation 100ml regulation, an OEM customer's inventory buffer, and a temporary standstill in Indian demand despite a recovering market were behind the weak top line.
- Industrial (IBU) decreased by 6.6% y/y to EUR 4.8m, compared to our EUR 5.1m estimate. Line scan demand remained modest, while TFT flat panel sales were strong in the APAC region. Food industry saw good demand.
- The BoD proposes a dividend per share of EUR 0.30 to be distributed for FY'25, compared to the EUR 0.26/0.25 Evli/consensus estimates.
- DT expects double-digit y/y revenue growth for Q1'26 and H1'26, as it had previously indicated.

Rating	+ Accumulate			
Q4'25	Actual	Evli	Year ago	Q3'25
Revenue	29.7	29.4	31.6	24.7
MBU	14.9	12.6	12.5	10.4
SBU	10.0	11.7	13.9	9.8
IBU	4.8	5.1	5.2	4.5
Adj. EBITA	3.7	3.7	5.2	2.8
Adj. EBITA-margin	12.4 %	12.6 %	16.3 %	11.4 %

Share price, EUR (Last trading day's closing price)	10.75
Target price, EUR	12.0
Latest change in recommendation	16-Apr-25
Latest report on company	27-Jan-26
Research paid by issuer:	YES
No. of shares outstanding, '000's	14 656
No. of shares fully diluted, '000's	14 656
Market cap, EURm	158
Free float, %	—
Exchange rate	—
Reuters code	DETEC.HE
Bloomberg code	DETEC FH
Average daily volume, EURm	0.1
Next interim report	05-Feb-26
Web site	deetee.com/investors/
Analyst	Joonas Ilvonen
E-mail	joonas.ilvonen@evli.com
Telephone	+358 44 430 9071

++ BUY + ACCUMULATE □ REDUCE □ SELL

KEY FIGURES

	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2023	103.8	8.2	7.9%	21.1	0.38	29.3	18	23.1	10.5%	0.23
2024	107.5	13.8	12.8%	16.9	0.76	20.2	18	14.3	7.5%	0.50
2025E	100.8	8.4	8.3%	5.8	0.40	26.8	1.3	15.7	3.7%	0.26
2026E	111.1	13.3	12.0%	4.2	0.63	16.9	1.2	9.8	2.6%	0.42
2027E	121.3	16.6	13.7%	8.3	0.91	11.8	1.1	7.8	5.3%	0.60
Market cap, EURm	158	Gearing 2025E, %	—	—33.0 %	CAGR EPS 2024–27, %				6.5 %	
Net debt 2025E, EURm	—27	Price/book 2025E		1.9	CAGR Sales 2024–27, %				4.1 %	
Enterprise value, EURm	131	Dividend yield 2025E, %		2.5 %	ROE 2025E, %				7.2 %	
Total assets 2025E, EURm	101	Tax rate 2025E, %		20.3 %	ROCE 2025E, %				10.0 %	
Goodwill 2025E, EURm	0	Equity ratio 2025E, %		79.6 %	PEG, P/E 25/CAGR				0.7	

All the important disclosures can be found on the last pages of this report.

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. The valuation assumptions used are sensitive to changes and can significantly affect fair values. A change of a single percentage point in any used assumption could affect fair values by more than +/-20%. Recommendations and changes by analysts are available at [Analysts' recommendations and ratings revisions](#).

Investment recommendations are defined as follows:

Target price compared to share price	Recommendation
< -10 %	SELL
-10 – 0 %	REDUCE
0 – (+10) %	ACCUMULATE
> 10 %	BUY

ERP may temporarily suspend the rating and, if applicable, the target price to comply with regulations and/or firm policies, in which case a NOT RATED classification is used.

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage on the 16th of May, 2025. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Joonas Ivonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [27.1.2026, 9:00]. This report has been published on [5.2.2026, 9:30].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

According to ERP's best knowledge, the issuer(s) of the securities does/(do) not hold in excess of 5% of the total issued share capital of the issuer(s).

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers FactSet and Bloomberg, stock-exchange releases from the companies and other company news, and publicly available online sources. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ('SEC'), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ('FINRA'). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Contact information**SALES, TRADING AND RESEARCH****Equity Sales & Trading**

Joachim Dannberg (head) +358 9 4766 9123
Aleksi Jalava +358 9 4766 9123
Pasi Väistönen +358 9 4766 9123

Evli Investment Solutions

Johannes Asuja +358 9 4766 9205

Equity Research

Jerker Salokivi (head) +358 9 4766 9149
Joonas Ilvonen +358 44 430 9071
Atte Jortikka +358 40 054 3725
Atte Pitkäjärvi +358 44 047 6597

EVLI

EVLI PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Internet www.evli.com
E-mail firstname.lastname@evli.com

**EVLI PLC,
STOCKHOLMSFILIAL**
Regeringsgatan 67 P.O. Box 16354
SE-103 26 Stockholm
Sverige
stockholm@evli.com
Tel +46 (0)8 407 8000